Vor BioPharma Inc (VOR)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$18.26-3.59%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Vor BioPharma Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.887
Annual ending 2026-12-31
Revenue	—	4.17M
EPS	—	-7.257
Annual ending 2027-12-31
Revenue	—	10M
EPS	—	-3.64

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Secure funding through private placements	This funding supports its cell therapy development through mid-2028.	Intact	failure to raise at least $75 million in any quarter if cash runway threatened	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Maintain cash runway into mid-2028	A primary condition in Vor BioPharma Inc's published investment case. The stated target is >= $450 million cash and equivalents.	Intact	cash falls below $300 million before mid-2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage operating losses to preserve cash	A supporting condition in Vor BioPharma Inc's published investment case. The stated target is Limit quarterly operating loss to less than $40 million.	Intact	quarterly operating loss exceeds $50 million persistently	Operating income: $-47.853M FY2026-Q2; GAAP. Published target: Limit quarterly operating loss to less than $40 million. Target period is not explicitly aligned with this observation. Source published Aug 11, 2026-47,853,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 7ca64bd3-48f3-42ea-a604-c25dc6c4d4c6. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.64

$-3.48 → $-3.64 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.48	$10,000,000	6 / 8
2026-07-25	$-3.48	$10,000,000	6 / 8
2026-07-26	$-3.48	$10,000,000	6 / 8
2026-07-27	$-3.48	$10,000,000	6 / 8
2026-07-28	$-3.48	$10,000,000	6 / 8
2026-07-29	$-3.74	$0	5 / 8
2026-07-30	$-3.74	$0	5 / 8
2026-07-31	$-3.48	$10,000,000	6 / 8
2026-08-01	$-3.48	$10,000,000	6 / 8
2026-08-02	$-3.48	$10,000,000	6 / 8
2026-08-03	$-3.74	$0	5 / 8
2026-08-04	$-3.74	$0	5 / 8
2026-08-05	$-3.48	$10,000,000	6 / 8
2026-08-06	$-3.48	$10,000,000	6 / 8
2026-08-08	$-3.48	$10,000,000	6 / 8
2026-08-09	$-3.74	$0	5 / 8
2026-08-10	$-3.48	$10,000,000	6 / 8
2026-08-12	$-3.48	$10,000,000	6 / 8
2026-08-13	$-3.74	$0	5 / 8
2026-08-14	$-3.48	$10,000,000	6 / 8
2026-08-15	$-3.48	$10,000,000	6 / 8
2026-08-16	$-3.48	$10,000,000	6 / 8
2026-08-17	$-3.48	$10,000,000	6 / 8
2026-08-18	$-3.48	$10,000,000	6 / 8
2026-08-19	$-3.48	$10,000,000	6 / 8
2026-08-20	$-3.60	$10,000,000	6 / 8
2026-08-21	$-3.60	$10,000,000	6 / 8
2026-08-22	$-3.60	$10,000,000	6 / 8
2026-08-23	$-3.60	$10,000,000	6 / 9
2026-08-24	$-3.60	$10,000,000	6 / 9
2026-08-25	$-3.60	$10,000,000	6 / 9
2026-08-26	$-3.60	$10,000,000	6 / 9
2026-08-27	$-3.60	$10,000,000	6 / 9
2026-08-28	$-3.60	$10,000,000	6 / 9
2026-08-29	$-3.60	$10,000,000	6 / 9
2026-08-30	$-3.60	$10,000,000	6 / 9
2026-08-31	$-3.60	$10,000,000	6 / 9
2026-09-01	$-3.60	$10,000,000	6 / 9
2026-09-02	$-3.60	$10,000,000	6 / 9
2026-09-03	$-3.60	$10,000,000	6 / 9
2026-09-04	$-3.60	$10,000,000	6 / 9
2026-09-05	$-3.60	$10,000,000	6 / 9
2026-09-06	$-3.60	$10,000,000	6 / 9
2026-09-07	$-3.60	$10,000,000	6 / 9
2026-09-08	$-3.60	$10,000,000	6 / 9
2026-09-09	$-3.60	$10,000,000	6 / 9
2026-09-10	$-3.60	$10,000,000	6 / 9
2026-09-11	$-3.60	$10,000,000	6 / 9
2026-09-12	$-3.60	$10,000,000	6 / 9
2026-09-13	$-3.60	$10,000,000	6 / 9
2026-09-14	$-3.60	$10,000,000	6 / 9
2026-09-15	$-3.60	$10,000,000	6 / 9
2026-09-16	$-3.60	$10,000,000	6 / 9
2026-09-17	$-3.60	$10,000,000	6 / 9
2026-09-18	$-3.60	$10,000,000	6 / 9
2026-09-19	$-3.60	$10,000,000	6 / 9
2026-09-20	$-3.60	$10,000,000	6 / 9
2026-09-21	$-3.60	$10,000,000	6 / 9
2026-09-22	$-3.60	$10,000,000	6 / 9
2026-09-23	$-3.60	$10,000,000	6 / 9
2026-09-24	$-3.60	$10,000,000	6 / 9
2026-09-25	$-3.60	$10,000,000	6 / 9
2026-09-26	$-3.60	$10,000,000	6 / 9
2026-09-27	$-3.60	$10,000,000	6 / 9
2026-09-28	$-3.60	$10,000,000	6 / 9
2026-09-29	$-3.60	$10,000,000	6 / 9
2026-09-30	$-3.60	$10,000,000	6 / 9
2026-10-01	$-3.60	$10,000,000	6 / 9
2026-10-02	$-3.60	$10,000,000	6 / 9
2026-10-03	$-3.60	$10,000,000	6 / 9
2026-10-04	$-3.60	$10,000,000	6 / 9
2026-10-05	$-3.60	$10,000,000	6 / 9
2026-10-06	$-3.60	$10,000,000	6 / 9
2026-10-07	$-3.60	$10,000,000	6 / 9
2026-10-08	$-3.60	$10,000,000	6 / 9
2026-10-09	$-3.60	$10,000,000	6 / 9
2026-10-10	$-3.60	$10,000,000	6 / 9
2026-10-11	$-3.60	$10,000,000	6 / 9
2026-10-12	$-3.60	$10,000,000	6 / 9
2026-10-13	$-3.60	$10,000,000	5 / 9
2026-10-14	$-3.60	$10,000,000	5 / 9
2026-10-15	$-3.60	$10,000,000	5 / 9
2026-10-16	$-3.65	$10,000,000	5 / 9
2026-10-17	$-3.65	$10,000,000	5 / 9
2026-10-18	$-3.65	$10,000,000	5 / 9
2026-10-19	$-3.65	$10,000,000	5 / 9
2026-10-20	$-3.65	$10,000,000	5 / 9
2026-10-21	$-3.65	$10,000,000	5 / 9
2026-10-22	$-3.64	$10,000,000	6 / 10
2026-10-23	$-3.64	$10,000,000	6 / 10
2026-10-24	$-3.64	$10,000,000	6 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	8	1
2026-06-01	8	1
2026-07-01	8	1
2026-08-01	8	1
2026-09-01	8	1
2026-10-01	9	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Secure funding through private placementsDirect metric needs a verified mapping
Maintain cash runway into mid-2028Direct metric needs a verified mapping
Manage operating losses to preserve cashOperating income: $-47.853M

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.5%Typical daily move · historical

Downside history

-75.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Vor BioPharma Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

VOR is a high-risk, early-stage biotechnology company rather than an established compounder. Its multi-year view is on watch: telitacicept has reached a regulatory milestone in China, but financial delivery remains limited and recent performance is weak.

What's priced into Vor BioPharma Inc

The evidence does not provide a valuation comparison or a clear account of market expectations, so whether VOR is cheap or expensive versus peers cannot be assessed. The available signal suggests the setup is not defined by a full combination of expensive valuation, weak execution, and turbulent sector conditions.

What the fundamentals likely do

Near term, operating losses and erratic results leave the next financial update exposed to execution risk; the snapshot flags a 50% miss probability. Over the multi-year view, global Phase 3 development and China’s conditional approval are important steps, while $450 million of cash runway into mid-2028 provides funding time but does not resolve ongoing losses.

What Vor BioPharma Inc hinges on

The thesis depends on telitacicept advancing through global Phase 3 trials and turning regulatory progress into financial delivery. Near-term guidance cuts or further weakening in jobs data could add pressure, while continued strength from healthcare bellwethers could support the sector backdrop.